Defense Diagnostics develops innovative point-of-care medical diagnostics focused on rethinking testing methodologies. The company provides solutions aimed at addressing significant societal health challenges through advanced diagnostic tools. Their offerings enable proactive testing for critical public health concerns.
Funding
Funding not disclosed
Founders
Product
Problem
Accidental fentanyl overdoses are a growing concern, often resulting from unknowingly ingesting fentanyl-laced substances. Traditional laboratory-based drug testing methods can be time-consuming and inaccessible, hindering timely intervention and harm reduction efforts.
Solution
Defense Diagnostics develops DEFENT, an all-in-one fentanyl detection device designed for rapid and accurate point-of-care testing. The device empowers individuals and communities with a user-friendly solution for identifying the presence of fentanyl in various substances. By providing on-the-spot results, DEFENT enables proactive measures to prevent accidental overdoses and reduce harm. The self-testing capabilities promote accessibility and convenience, allowing for more frequent and immediate drug testing in diverse settings.
Target Audience
The primary target audience includes individuals at risk of fentanyl exposure, harm reduction organizations, community health centers, and first responders.
Features
- Integrated system for sample collection, processing, and analysis in a single device
- High sensitivity and specificity for fentanyl detection
- Rapid results available within minutes
- User-friendly design for easy operation by individuals with minimal training
- Portable and self-contained for on-site testing